脂肪肝
肠道菌群
代谢综合征
疾病
医学
临床试验
肥胖
2型糖尿病
益生菌
胃肠病学
糖尿病
内科学
免疫学
生物
内分泌学
细菌
遗传学
作者
Chujin Cao,Mengxia Shi,Xiuru Wang,Ying Yao,Rui Zeng
标识
DOI:10.3389/fnut.2023.1155306
摘要
Non-alcoholic fatty liver disease (NAFLD) is a global public health issue, of which the prevalence is about 25% worldwide. The incidence of NAFLD is increasing in patients with obesity, type 2 diabetes (T2DM) and the metabolic syndrome. The crosstalk between gut microbiota and metabolism-related diseases has been raised great concern. Patients with NAPLD were observed with disruption of gut microbiota. Several researches showed that gut microbiota was the determination in the progression of NAFLD by the experiments using fecal microbiota transplants. The application of probiotics, as one of the most important strategies for the regulation of gut microbiota disorder, have been explored whether it is beneficial to gut-related diseases of intestine-distal organs. Some probiotics were showed to improve the liver parameters and phenotype in patients with NAFLD. The oral intake of them might become the effective management for the prevention and treatment of NAFLD. In this review, we summarized the human clinical trials focusing on the effects of probiotics on NAFLD to give some evidential reference for the administration of NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI